In the absence of definitive medical treatment for severe fulminant hepatic failure, liver transplantation may be appropriate in selected patients. However, uniform and easily applicable criteria for diagnosis of severity and analysis of results are needed to prevent unnecessary transplantation and to ensure that patients who may benefit are appropriately treated. Previous regimens for treatment of fulminant hepatic failure were often advocated, on the basis of data from historical controls, for several years until controlled trials failed to show any benefit. To obtain reliable information more rapidly than achieved before, a controlled trial between specialist liver transplant units is needed to establish the role of emergency hepatic transplantation in patients with fulminant hepatic failure.

Type

Journal article

Journal

Lancet

Publication Date

06/01/1990

Volume

335

Pages

32 - 35

Keywords

Biomedical and Behavioral Research, Health Care and Public Health, Professional Patient Relationship, Acute Disease, Bias (Epidemiology), Control Groups, Ethics, Medical, Hemoperfusion, Hepatic Encephalopathy, Humans, Liver Transplantation, Patient Selection, Prognosis, Randomized Controlled Trials as Topic, Renal Dialysis, Research Subjects, Risk Assessment, Severity of Illness Index, Therapeutic Human Experimentation